Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNK1 siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
TNK1 siRNA is a double-stranded RNA molecule designed to silence the expression of the Tyrosine Kinase Non-Receptor 1 (TNK1) gene through the RNA interference (RNAi) pathway. TNK1, also known as Kos1, is a non-receptor tyrosine kinase that has been implicated as an oncogenic driver in various malignancies, including Hodgkin lymphoma and certain subsets of acute myeloid leukemia (AML). By binding to the TNK1 messenger RNA (mRNA) and inducing its degradation, TNK1 siRNA prevents the translation of the TNK1 protein, thereby inhibiting downstream signaling pathways such as STAT3 and AKT that promote cell survival and proliferation. While primarily utilized as a research tool to validate TNK1 as a therapeutic target, siRNA-based approaches against TNK1 are being explored for their potential to treat cancers characterized by TNK1 overactivation or gene fusions.
- Other names
- TNK1 small interfering RNATNK-1 small interfering RNATNK 1 small interfering RNAKos1 siRNAKos-1 siRNAKos 1 siRNATyrosine kinase non-receptor 1 siRNA
02
Targets
IFIH1 (MDA5)TLR3 (Toll-like receptor 3)TLR7/8 (Toll-like receptor 7 and Toll-like receptor 8)TNK1 (Tyrosine kinase non receptor 1)
Beyond the preview
Go deeper on TNK1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNK1 siRNA.